{"drugs":["Auranofin","Ridaura"],"mono":{"0":{"id":"50660-s-0","title":"Generic Names","mono":"Auranofin"},"1":{"id":"50660-s-1","title":"Dosing and Indications","sub":[{"id":"50660-s-1-4","title":"Adult Dosing","mono":"<b>Rheumatoid arthritis:<\/b> 6 mg ORALLY once daily or 3 mg ORALLY twice daily, MAX 9 mg\/day"},{"id":"50660-s-1-5","title":"Pediatric Dosing","mono":"<ul><li>Not FDA approved in children<\/li><li><b>Rheumatoid arthritis:<\/b> initial, 0.1 mg\/kg\/day ORALLY; maintenance, 0.15 mg\/kg\/day ORALLY; MAX dose, 0.2 mg\/kg\/day<\/li><\/ul>"},{"id":"50660-s-1-6","title":"Dose Adjustments","mono":"<ul><li><b>hemodialysis:<\/b> supplemental dosing after dialysis is not required<\/li><li><b>renal impairment:<\/b> 3 mg ORALLY once daily or every other day<\/li><\/ul>"},{"id":"50660-s-1-7","title":"Indications","mono":"<b>FDA-Labeled Indications<\/b><br\/>Rheumatoid arthritis<br\/>"}]},"2":{"id":"50660-s-2","title":"Black Box Warning","mono":"<b>Oral (Capsule)<\/b><br\/>Auranofin contains gold and can cause gold toxicity, signs of which include: fall in hemoglobin, leukopenia below 4000 WBC\/mm(3), granulocytes below 1500\/mm(3), decrease in platelets below 150,000\/mm(3), proteinuria, hematuria, pruritus, rash, stomatitis or persistent diarrhea. Review laboratory work before writing each auranofin prescription. Auranofin is only indicated for use in selected patients with active rheumatoid arthritis. <br\/>"},"3":{"id":"50660-s-3","title":"Contraindications\/Warnings","sub":[{"id":"50660-s-3-9","title":"Contraindications","mono":"<ul><li>anaphylactic reactions due to gold<\/li><li>bone marrow aplasia due to gold<\/li><li>exfoliative dermatitis due to gold<\/li><li>hematological disorders due to gold<\/li><li>necrotizing enterocolitis due to gold<\/li><li>pulmonary fibrosis due to gold<\/li><\/ul>"},{"id":"50660-s-3-10","title":"Precautions","mono":"<ul><li>myelosuppression may occur; monitoring required and discontinuation necessary if suspected<\/li><li>bone marrow depression, history of<\/li><li>exfoliative dermatitis has occurred<\/li><li>hepatocellular disease<\/li><li>inflammatory bowel disease<\/li><li>interstitial pneumonitis and fibrosis have occurred<\/li><li>nephrotic syndrome or glomerulitis, with proteinuria and hematuria may occur; discontinue if suspected<\/li><li>renal disease, progressive<\/li><li>skin rash<\/li><li>ulcerative enterocolitis has occurred; monitor<\/li><\/ul>"},{"id":"50660-s-3-11","title":"Pregnancy Category","mono":"<ul><li>C (FDA)<\/li><li>B3 (AUS)<\/li><\/ul>"},{"id":"50660-s-3-12","title":"Breast Feeding","mono":"Micromedex: Infant risk cannot be ruled out.<br\/>"}]},"4":{"id":"50660-s-4","title":"Drug Interactions","sub":{"1":{"id":"50660-s-4-14","title":"Major","mono":"<ul>Penicillamine (established)<\/ul>"}}},"5":{"id":"50660-s-5","title":"Adverse Effects","mono":"<b>Common<\/b><ul><li><b>Dermatologic:<\/b>Dermatitis, Pruritus (17%), Rash (24% to 26%)<\/li><li><b>Gastrointestinal:<\/b>Diarrhea (42.5% to 50%), Indigestion (3% to 9%), Loss of appetite (3% to 9%), Nausea (10%), Stomatitis (10% to 13%)<\/li><li><b>Ophthalmic:<\/b>Conjunctivitis (3% to 10%)<\/li><li><b>Renal:<\/b>Proteinuria (0.9% to 9%)<\/li><\/ul><b>Serious<\/b><ul><li><b>Gastrointestinal:<\/b>Gastrointestinal hemorrhage (0.1% to 1%), Ulcerative enterocolitis (less than 1%)<\/li><li><b>Hematologic:<\/b>Leukopenia (1% to 3%), Neutropenic disorder (0.1% to 1%), Thrombocytopenia (0.9% to 3%)<\/li><li><b>Hepatic:<\/b>Jaundice (less than 0.1%)<\/li><li><b>Respiratory:<\/b>Pneumonitis (less than 0.1%), Pulmonary toxicity<\/li><li><b>Other:<\/b>Angioedema (less than 0.1%)<\/li><\/ul>"},"6":{"id":"50660-s-6","title":"Drug Name Info","sub":{"0":{"id":"50660-s-6-17","title":"US Trade Names","mono":"Ridaura<br\/>"},"2":{"id":"50660-s-6-19","title":"Class","mono":"<ul><li>Antirheumatic<\/li><li>Gold Compound<\/li><\/ul>"},"3":{"id":"50660-s-6-20","title":"Regulatory Status","mono":"RX<br\/>"},"4":{"id":"50660-s-6-21","title":"Generic Availability","mono":"No<br\/>"}}},"7":{"id":"50660-s-7","title":"Mechanism Of Action","mono":"Auranofin is a gold-containing agent used in the treatment of patients with adult rheumatoid arthritis. The mechanism of action remains unknown, however it is known to modify disease activity as reflected by laboratory parameters such as erythrocyte sedimentation rate, and manifested by synovitis and associated symptoms.<br\/>"},"8":{"id":"50660-s-8","title":"Pharmacokinetics","sub":[{"id":"50660-s-8-23","title":"Absorption","mono":"Bioavailability: (rheumatoid arthritis), approximately 25% of the gold <br\/>"},{"id":"50660-s-8-24","title":"Distribution","mono":"Protein binding: (rheumatoid arthritis), 60% <br\/>"},{"id":"50660-s-8-25","title":"Metabolism","mono":"Rapidly metabolized <br\/>"},{"id":"50660-s-8-26","title":"Excretion","mono":"<ul><li>Fecal: (rheumatoid arthritis), remainder from renal excretion<\/li><li>Renal: (rheumatoid arthritis), 15% (approximately 60% of absorbed gold)<\/li><\/ul>"},{"id":"50660-s-8-27","title":"Elimination Half Life","mono":"Rheumatoid arthritis: 80 days (42 days to 128 days) <br\/>"}]},"10":{"id":"50660-s-10","title":"Monitoring","mono":"<ul><li>improved range of motion, decreased early morning stiffness and painful\/swollen joints, C-reactive protein levels, erythrocyte sedimentation rate<\/li><li>CBC with differential, platelet count, urinalysis; baseline, then monthly thereafter<\/li><li>liver function, renal function<\/li><\/ul>"},"11":{"id":"50660-s-11","title":"How Supplied","mono":"<b>Ridaura<\/b><br\/>Oral Capsule: 3 MG<br\/>"},"12":{"id":"50660-s-12","title":"Toxicology","sub":[{"id":"50660-s-12-31","title":"Clinical Effects","mono":"<b>GOLD DRUGS<\/b><br\/>OVERDOSE: Overdose data are limited. Overdose effects would be expected to be an extension of adverse effects seen at therapeutic doses. Ventricular tachycardia was reported after acute overdose in one case. ADVERSE EFFECTS: Common problems with therapeutic use include allergic dermatitis (12% to 55%), stomatitis, alopecia, hypersensitivity pneumonitis, drug-induced lupus, and rarely thrombocytopenia (incidence about 1%).<br\/>"},{"id":"50660-s-12-32","title":"Treatment","mono":"<b>GOLD DRUGS <\/b><br\/><ul><li>Decontamination: Metallic gold is poorly adsorbed by activated charcoal. Experience with activated charcoal following gold toxicities is limited.<\/li><li>Support:  If a toxic reaction occurs during therapeutic administration, discontinue the use of the drug.  Often, toxicity is reversible on discontinuation alone. The primary treatment for gold toxicity has been patient support during any hematologic, respiratory, and\/or gastrointestinal reactions.  Chelation has been used to reduce the amount of circulating gold, but its efficacy is unclear.  It is nearly impossible to remove all the gold from the body.<\/li><\/ul>"},{"id":"50660-s-12-33","title":"Range of Toxicity","mono":"<b>GOLD DRUGS<\/b><br\/>TOXICITY: There appears to be little correlation between total gold dose and toxicity. In a summary of 20 cases of toxicity after therapeutic use, the cumulative toxic dose was from 230 mg to 10 g of gold salt. Acute administration of intramuscular aurothioglucose 500 mg in one adult and 1000 mg in another did not cause acute toxicity. THERAPEUTIC DOSE: GOLD SODIUM THIOMALATE (ADULT) - Initial: 10 mg IM 1st week, 25 mg IM 2nd week, then 25 to 50 mg IM weekly until response, toxicity or 1 g cumulative dose. Maintenance with continued clinical improvement: 25 to 50 mg IM every other week, then every third week, then every fourth week as tolerated. GOLD SODIUM THIOMALATE (PEDIATRIC) - Test dose of 10 mg IM, then 1 mg\/kg (maximum 50 mg\/dose) IM weekly for 20 wk; maintenance, 1 mg\/kg IM (maximum 50 mg\/dose) every 2 to 4 weeks. <br\/>"}]},"13":{"id":"50660-s-13","title":"Clinical Teaching","mono":"<ul><li>This drug may cause alopecia, dermatitis, pruritus, urticaria, constipation, diarrhea, dyspepsia, loss of appetite, nausea, stomach cramps, stomatitis, vomiting, or conjunctivitis.<\/li><li>Patient should report signs\/symptoms of gold toxicity (anemia, leukopenia, hematuria, rash, stomatitis, persistent diarrhea).<\/li><li>Instruct patient to report signs\/symptoms of myelosuppression.<\/li><\/ul>"}}}